Bragar Eagel & Squire, PC reminds investors that class action lawsuits have been filed… | Your money

NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, reminds investors that class action lawsuits have been filed on behalf of shareholders of First Solar, Inc. (NASDAQ: FSLR), eHealth, Inc. (NASDAQ: EHTH) and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP, NRXPW). Shareholders have until the deadlines below to ask the court to serve as lead plaintiff. Additional information on each case can be found at the link provided.

First Solar, Inc. (NASDAQ: FSLR)

Course period: February 22, 2019 – February 20, 2020

Lead Applicant Deadline: March 8, 2022

On January 15, 2020, Barclays reported that First Solar had “apparently been, largely, priced out of the U.S. downstream solar market” and that the company had concealed its rapidly declining market share through misleading financial reports by including projects in its Project Development Pipeline that had actually been completed in previous years.

On this news, First Solar’s stock fell $4.03, or 7%, to close at $54.75 per share on January 15, 2020, hurting investors.

Then, on February 6, 2020, Barclays said that, in an attempt to regain market share, First Solar was “bidding more aggressively, driving down [Project Development contract] price, and finally reduce margins.

On this news, First Solar’s stock fell $0.45 to close at $52.65 per share on Feb. 6, 2020, further hurting investors.

Then, on February 20, 2020, First Solar announced that it was considering selling its project development business. The company also revealed that it was experiencing “challenges with certain aspects of the overall cost per watt” and that it would not meet its cost per watt targets.

On this news, First Solar’s stock fell $8.73, or 15%, to close at $50.59 per share on Feb. 21, 2020, further hurting investors.

For more information on the First Solar class action, please visit:

eHealth, Inc. (NASDAQ: EHTH)

Course period: April 26, 2018 – July 23, 2020

Lead Applicant Deadline: March 18, 2022

eHealth is a health insurance broker that focuses on selling Medicare-related policies on behalf of private insurers. Its primary source of revenue is commissions from the sale of Medicare Advantage, Medicare Supplement, and Medicare Part D prescription drug policies. On January 1, 2018, eHealth adopted and implemented a new accounting standard for revenue recognition. This standard, hereafter referred to as Accounting Standard Codification 606 or ASC 606, allowed eHealth to immediately recognize all of the commissions it expected to receive over the expected life of the policies. Although eHealth sold annual policies that could be canceled at any time by the consumer, it assumed that its policies would be renewed for several years. Therefore, for many of eHealth’s Medicare-related policies, it recognized between three and five years of commissions immediately after the policy was sold.

The lawsuit in the class action alleges that the assumption that eHealth customers would renew their policies was unrealistic and contrary to eHealth’s recent experience with cancellations and renewals. Beginning in 2017, eHealth began soliciting Medicare customers with television advertising. The late night ads offering $0 monthly bonuses actually generated an increase in customers in a short period of time. Between 2017 and 2018, the number of Medicare-related insurance claims submitted to eHealth by claimants increased by 39%. These customers, however, were known to cancel their policies over short periods of time, leading eHealth to experience skyrocketing “membership turnover” rates, i.e. the percentage of customers who cancel their policies in the first year. Nevertheless, eHealth was able to provide analysts and investors with record earnings due to the fact that it was able to recognize in advance and immediately three to five year commission earnings for these policies.

The complaint further alleges that class members were materially harmed by eHealth’s false and misleading statements. As a direct result of defendants’ materially false and misleading statements, eHealth’s stock price artificially rose from a relatively flat price of approximately $15.32 per common share on March 19, 2018 to $136.32 before April 8, 2020. It was that day. that Muddy Waters Capital, a well-known and well-respected research firm, released a report exposing eHealth’s accounting misconduct. The report revealed, among other things, that eHealth’s “very aggressive accounting masks” [] a significantly unprofitable business”, “that the primary driver of growth since 2018 has been EHTH’s reliance on direct response television advertising, which attracts an unprofitable and high churn subscriber”, “that the assumptions persistence of EHTH in its LTV model [under ASC 606] seem very aggressive compared to reality. The Muddy Waters report also found that eHealth’s financial statements for 2019: (a) overstated revenue by $128 million; (b) an overstated operating profit of $263 million; and (c) understated an operating loss of -$181 million. The Muddy Waters report led to a sharp decline in eHealth’s stock price, which fell to $103.20 per share.

Subsequently, on July 23, 2020, when eHealth announced its results for the second quarter of fiscal 2020, its share price fell again as information in its announcement confirmed substantial aspects of the allegations of “membership churn” previously asserted in the Muddy Waters. report. In response, eHealth’s stock price fell from a closing price of $114 per share on July 23, 2020 to $79.17 per share on July 24, 2020.

For more information on the eHealth class action, please visit:

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP, NRXPW)

Course period: June 1, 2021 – November 4, 2021

Lead Applicant Deadline: March 21, 2022

NRx is a clinical-stage small molecule pharmaceutical company developing various therapies for the treatment of central nervous system disorders and life-threatening lung diseases. The Company’s products include, among others, ZYESAMI, an investigational pre-commercial drug for respiratory failure related to COVID-19.

In June 2021, NRx announced that it had filed an application with the United States Food and Drug Administration (“FDA”) seeking an Emergency Use Authorization (“EUA”) for ZYESAMI (Aviptadil-Acetate ) to treat critically ill COVID-19 patients with respiratory failure. (the “EUA ZYESAMI Application”).

The Complaint alleges that throughout the Class Period, the Defendants made materially false and misleading statements regarding the company’s business, operations and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) ZYESAMI’s EUA application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (ii) as a result, the FDA was unlikely to approve ZYESAMI’s EUA application in its current form; and (iii) as a result, the Company’s public statements were materially false and misleading at all material times.

On November 4, 2021, NRx issued a press release “announcing[ing] that the [FDA] refused to issue a [EUA] for ZYESAMI® (aviptadil). The FDA has said it is unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the drug and the known and potential risks of ZYESAMI in patients with COVID-19. critical with respiratory failure.

On this news, NRx stock price fell $2.27 per share, or 25.45%, to close at $6.65 per share on November 5, 2021.

For more information on the NRx Pharmaceuticals class action, please visit:

About Bragar Eagel & Squire, PC:

Bragar Eagel & Squire, PC is a nationally recognized law firm with offices in New York, California and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivatives and other complex litigation before state and federal courts across the country. For more company information, please visit Lawyer advertisement. Prior results do not guarantee similar results.

Contact details:

Bragar Eagel & Squire, CP Brandon Walker, Esq. Alexandra B. Raymond, Esq. (212) 355-4648

Comments are closed.